Evidence map›Paper›PMID 42808865›Full record

ArticleBJU international2026

The effect of time to nephrectomy on cancer-specific mortality in pathological T stage (pT)1b-2 renal cancer.

Michele Nicolazzini, Federico Polverino, Leonardo Quarta, Maximilian Filzmayer, Michele Petix, Calogero Catanzaro, Nick Lee, Jordan A Goyal, Nicola Longo, Gennaro Musi and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Michele NicolazziniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID https://orcid.org/0009-0003-7773-5101
Federico PolverinoCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID https://orcid.org/0009-0007-6218-3761
Leonardo QuartaCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID https://orcid.org/0009-0008-9523-3400
Maximilian FilzmayerCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID https://orcid.org/0009-0005-5715-9965
Michele PetixCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID https://orcid.org/0009-0009-2893-2196
Calogero CatanzaroCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID https://orcid.org/0009-0004-6265-5288
Nick LeeCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0002-7166-0503
Jordan A GoyalCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID https://orcid.org/0009-0006-4609-8981
Nicola LongoDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.ORCID https://orcid.org/0009-0009-3394-0596
Gennaro MusiDivision of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Felix K H ChunDepartment of Urology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.ORCID https://orcid.org/0000-0001-8486-9536
Alberto BrigantiDepartment of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Riccardo SchiavinaDivision of Urology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Carlotta PalumboDivision of Urology, Department of Translational Medicine, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.ORCID https://orcid.org/0000-0002-6165-5276
Alessandro VolpeDivision of Urology, Department of Translational Medicine, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.ORCID https://orcid.org/0000-0003-3377-3782
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the impact of prolonged time to surgery on cancer-specific mortality (CSM) in patients with pathological T stage (pT)1b-2 N0M0 renal cell carcinoma (RCC) treated with nephrectomy (either partial [PN] or radical [RN]). Within the Surveillance, Epidemiology and End Results (SEER) database (2004-2021), we tested the effect of time to surgery >3 vs ≤3 months on CSM in patients with pT1b-2N0M0 RCC. PATIENTS AND

methodsPropensity score matching (PSM) and multivariable competing risks regression (CRR) were performed. Subgroup analyses stratified patients according to time to surgery interval (≤1 vs 1-3 months, ≤3 vs 3-6 months, ≤3 vs >6 months), histotype, and grade.

resultsOf 16 322 patients with pT1b-2 RCC treated with nephrectomy, time to surgery >3 months was recorded in 3023 (18%) patients. These patients were older (median age 64 vs 62 years) and harboured a smaller proportion of pT2 patients (19% vs 30%). After one-to-one PSM, 3023 (100%) patients with a time to surgery >3 months exhibited a 60-month CSM of 7.6% vs 5.9% in 3023 (23%) patients with a time to surgery ≤3 months. In CRR time to surgery >3 months independently predicted 1.3-fold higher CSM (P = 0.02). Subgroup analyses revealed a dose-response effect, with a CSM increase in 1.3-fold fashion when time to surgery was 3-6 months vs 1.6-fold fashion when time to surgery was >6 months. The detrimental effect of time to surgery>3 months was consistent across all grades but was not evidenced among patients with a non-clear cell RCC.

conclusionIn patients with pT1b-2N0M0 treated with either PN or RN, prolonged time from diagnosis to surgery was associated with higher CSM. This association was not observed among patients with non-clear cell RCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNephrectomyTime-to-TreatmentAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPropensity ScoreSEER ProgramTime FactorsTreatment Delaykidney cancernephrectomyrenal cell carcinomasurgical delaySurveillance, Epidemiology and End Results (SEER)

Identifiers

PMID42808865
PMCPMC13741110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.